INOVIO PHARMACEUTICALS, INC. Accrued Liabilities for Commissions, Expense and Taxes
INOVIO PHARMACEUTICALS, INC. (INO) had Accrued Liabilities for Commissions, Expense and Taxes of $162.10 million as of 2021-01-25, per its 10-Q filed 2021-11-09.
Discontinued › Notes › Financial Services
us-gaap:AccruedLiabilitiesForCommissionsExpenseAndTaxes · last filed 2021-11-09
- 2021-01-25: Accrued Liabilities for Commissions, Expense and Taxes $162.10M.
| Period end | Accrued Liabilities for Commissions, Expense and Taxes |
|---|---|
| 2021-01-25 | $162.10M 10-Q · filed 2021-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |